Predicting changes in hypertension control using electronic health records from a chronic disease management program
暂无分享,去创建一个
Jimeng Sun | Joshua C. Denny | Bradley Malin | Aris Gkoulalas-Divanis | Thomas A. Lasko | Adam Perer | Candace D. McNaughton | Ping Zhang | Jacqueline Kirby | Alexander Saip | Jimeng Sun | B. Malin | T. Lasko | J. Denny | Ping Zhang | A. Gkoulalas-Divanis | J. Kirby | C. McNaughton | Alexander Saip | Adam Perer | Jacqueline Kirby
[1] A. Huebschmann,et al. Reducing Clinical Inertia in Hypertension Treatment: A Pragmatic Randomized Controlled Trial , 2012, Journal of clinical hypertension.
[2] A. Dominiczak,et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.
[3] A. Dominiczak,et al. 2007 ESH‐ESC Guidelines for the management of arterial hypertension , 2007 .
[4] Leo Breiman,et al. Random Forests , 2001, Machine Learning.
[5] Daniel W. Jones,et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.
[6] A. Zanchetti,et al. Cohort profile: The Gubbio Population Study. , 2014, International journal of epidemiology.
[7] D. Lackland,et al. Hypertension risk prediction: an important but complicated assessment. , 2010, Hypertension.
[8] Farzad Hadaegh,et al. A point-score system superior to blood pressure measures alone for predicting incident hypertension: Tehran Lipid and Glucose Study , 2011, Journal of hypertension.
[9] Suzette J. Bielinski,et al. Use of diverse electronic medical record systems to identify genetic risk for type 2 diabetes within a genome-wide association study , 2012, J. Am. Medical Informatics Assoc..
[10] Michael Böhm,et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Journal of hypertension.
[11] Abel N. Kho,et al. A Highly Specific Algorithm for Identifying Asthma Cases and Controls for Genome-Wide Association Studies , 2009, AMIA.
[12] Geoffrey A Head,et al. Definition of ambulatory blood pressure targets for diagnosis and treatment of hypertension in relation to clinic blood pressure: prospective cohort study , 2010, BMJ : British Medical Journal.
[13] Fei Wang,et al. ICDA: A Platform for Intelligent Care Delivery Analytics , 2012, AMIA.
[14] Morris J. Brown,et al. Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs , 2002, Journal of hypertension.
[15] Brian W. Ward,et al. Prevalence of Multiple Chronic Conditions Among US Adults: Estimates From the National Health Interview Survey, 2010 , 2013, Preventing chronic disease.
[16] Eric Boerwinkle,et al. Demographic, environmental, and genetic predictors of metabolic side effects of hydrochlorothiazide treatment in hypertensive subjects. , 2005, American journal of hypertension.
[17] W. Kannel,et al. Some lessons in cardiovascular epidemiology from Framingham. , 1976, The American journal of cardiology.
[18] Ulrich Tholl,et al. Measuring blood pressure: pitfalls and recommendations. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[19] Christopher G. Chute,et al. A Genome-Wide Association Study of Red Blood Cell Traits Using the Electronic Medical Record , 2010, PloS one.
[20] Barry R. Davis,et al. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. , 2000, JAMA.
[21] Michael Böhm,et al. Antihypertensive drug therapy and blood pressure control in men and women: an international perspective , 2010, Journal of Human Hypertension.
[22] Carl J Pepine,et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. , 2003, JAMA.
[23] Bernard J. Gersh,et al. Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention , 2007, Circulation.
[24] D. Levy,et al. A Risk Score for Predicting Near-Term Incidence of Hypertension: The Framingham Heart Study , 2008, Annals of Internal Medicine.
[25] Barry R Davis,et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. , 2005, JAMA.
[26] Arno Lukas,et al. Body mass index is the main risk factor for arterial hypertension in young subjects without major comorbidity , 2003, European journal of clinical investigation.
[27] H. Perry,et al. Antihypertensive efficacy of treatment regimens used in Veterans Administration hypertension clinics. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. , 1998, Hypertension.
[28] W. Cushman,et al. Home and clinic blood pressure responses in elderly individuals with systolic hypertension. , 2012, Journal of the American Society of Hypertension : JASH.
[29] A. Dominiczak,et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. , 2007, Journal of hypertension.
[30] Lin Chen,et al. Importance of multi-modal approaches to effectively identify cataract cases from electronic health records , 2012, J. Am. Medical Informatics Assoc..
[31] Fei Wang,et al. Combining Knowledge and Data Driven Insights for Identifying Risk Factors using Electronic Health Records , 2012, AMIA.
[32] Barry R. Davis,et al. Outcomes in Hypertensive Black and Nonblack Patients Treated With Chlorthalidone, Amlodipine, and Lisinopril , 2005 .
[33] Devin M Mann,et al. Comparison of the Framingham Heart Study Hypertension Model With Blood Pressure Alone in the Prediction of Risk of Hypertension: The Multi-Ethnic Study of Atherosclerosis , 2010, Hypertension.
[34] Melissa A. Basford,et al. Validation of electronic medical record-based phenotyping algorithms: results and lessons learned from the eMERGE network. , 2013, Journal of the American Medical Informatics Association : JAMIA.
[35] Morris J. Brown,et al. Personalised medicine for hypertension , 2011, BMJ : British Medical Journal.
[36] J. Cutler,et al. Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. , 1993, JAMA.
[37] Y. Kawano,et al. Comparison of first-line antihypertensive drugs by a randomized cross-over method--a preliminary report. , 1995, Hypertension research : official journal of the Japanese Society of Hypertension.
[38] V. Durkalski,et al. Therapeutic Inertia Is an Impediment to Achieving the Healthy People 2010 Blood Pressure Control Goals , 2006, Hypertension.
[39] C. Lewis,et al. Treatment of Mild Hypertension Study: Final Results , 1993 .
[40] D. Roden,et al. Development of a Large‐Scale De‐Identified DNA Biobank to Enable Personalized Medicine , 2008, Clinical pharmacology and therapeutics.
[41] Roland E Schmieder,et al. Clinical situations associated with difficult-to-control hypertension , 2013, Journal of hypertension.
[42] Vital signs: awareness and treatment of uncontrolled hypertension among adults--United States, 2003-2010. , 2012, MMWR. Morbidity and mortality weekly report.
[43] Jiang He,et al. Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. , 2002, JAMA.
[44] Hua Xu,et al. Portability of an algorithm to identify rheumatoid arthritis in electronic health records , 2012, J. Am. Medical Informatics Assoc..
[45] David A Calhoun,et al. Pathogenesis of Hypertension , 2003, Annals of Internal Medicine.
[46] Domingo Orozco-Beltrán,et al. Clinical Inertia in Poorly Controlled Elderly Hypertensive Patients: A Cross-Sectional Study in Spanish Physicians to Ascertain Reasons for Not Intensifying Treatment , 2013, American Journal of Cardiovascular Drugs.
[47] Edward B. Nelson,et al. The treatment of mild hypertension study. , 1993 .
[48] I. Kohane,et al. Electronic medical records for discovery research in rheumatoid arthritis , 2010, Arthritis care & research.
[49] Thomas Hedner,et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study , 2000, The Lancet.
[50] A. Scuteri,et al. Do hypertensive individuals have enlarged aortic root diameters? Insights from studying the various subtypes of hypertension. , 2008, American journal of hypertension.
[51] Wenyaw Chan,et al. Effect of a Physician Uncertainty Reduction Intervention on Blood Pressure in Uncontrolled Hypertensives—A Cluster Randomized Trial , 2012, Journal of General Internal Medicine.
[52] B Waeber,et al. Individual responses to converting enzyme inhibitors and calcium antagonists. , 1988, Hypertension.
[53] Tara Gomes,et al. Chlorthalidone Versus Hydrochlorothiazide for the Treatment of Hypertension in Older Adults , 2013, Annals of Internal Medicine.
[54] Peggy L Peissig,et al. Cataract research using electronic health records , 2011, BMC ophthalmology.
[55] M. J. Ashby,et al. Optimisation of antihypertensive treatment by crossover rotation of four major classes , 1999, The Lancet.
[56] Daniel W. Jones,et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.
[57] B. Waeber,et al. Therapeutic strategies to improve control of hypertension , 2013, Journal of hypertension.
[58] B. Davis,et al. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.
[59] J. Izzo,et al. Mechanisms and management of hypertensive heart disease: from left ventricular hypertrophy to heart failure. , 2004, The Medical clinics of North America.
[60] Jun Ma,et al. Screening, Treatment, and Control of Hypertension in US Private Physician Offices, 2003–2004 , 2008, Hypertension.